These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9393292)

  • 1. Construction and validation of a short-form benign prostatic hypertrophy health-related quality-of-life questionnaire. BPH Group in General Practice.
    Lukacs B; Comet D; Grange JC; Thibault P
    Br J Urol; 1997 Nov; 80(5):722-30. PubMed ID: 9393292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prospective follow-up of 3,228 patients suffering from clinical benign prostatic hyperplasia (BPH) treated for 3 years wi alfuzosin in general practice. BPH Group in General Practice].
    Lukacs B; Grange JC; Comet D; Mc Carthy C
    Prog Urol; 1999 Apr; 9(2):271-80. PubMed ID: 10370951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term quality of life in patients with benign prostatic hypertrophy: preliminary results of a cohort survey of 7,093 patients treated with an alpha-1-adrenergic blocker, alfuzosin. QOL BPH Study Group in General Practice.
    Lukacs B; McCarthy C; Grange JC
    Eur Urol; 1993; 24 Suppl 1():34-40. PubMed ID: 7687557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.
    Lukacs B; Leplège A; Thibault P; Jardin A
    Urology; 1996 Nov; 48(5):731-40. PubMed ID: 8911517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia.
    Hansen BJ; Flyger H; Brasso K; Schou J; Nordling J; Thorup Andersen J; Mortensen S; Meyhoff HH; Walter S; Hald T
    Br J Urol; 1995 Oct; 76(4):451-8. PubMed ID: 7551880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice.
    Lukacs B; Grange JC; Comet D
    Urology; 2000 Apr; 55(4):540-6. PubMed ID: 10736498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reproducibility and clinical and concurrent validity of the MSF-4: a four-item male sexual function questionnaire for patients with benign prostatic hyperplasia.
    Marquis P; Marrel A
    Value Health; 2001; 4(4):335-43. PubMed ID: 11705301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Quality of life assessment of the male with benign prostate hypertrophy].
    Nekić VC; Tiljak H; Petricek G; Soldo D; Nekić G; Buljan N
    Acta Med Croatica; 2007 Feb; 61(1):49-55. PubMed ID: 17593641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of alfuzosin on quality of life in benign prostatic hyperplasia patients: preliminary results. Italian Alfuzosin Co-Operative Group.
    Martelli A; Pacifico P; Casadei G
    Eur Urol; 1993; 24 Suppl 1():28-33. PubMed ID: 7687556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin].
    Mazo EB; Matushevskiĭ IA; Nikitin IuIu
    Ter Arkh; 1997; 69(10):79-82. PubMed ID: 9471799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter observational trial on symptomatic treatment of benign prostatic hyperplasia with alfuzosin: clinical evaluation of impact on patient's quality of life. The Italian Alfuzosin Cooperative Group.
    Eur Urol; 1995; 27(2):128-34. PubMed ID: 7538083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Impact of alfuzosin 10 mg once daily on quality of life in Tunisian patients with lower urinary symptoms suggestive of benign prostatic hyperplasia].
    Ben Rhouma S; H'sairi M; Adbi H; Binous MY; Nouira Y; Ben Raies N; Mosbah AT; Horchani A
    Tunis Med; 2015 Mar; 93(3):164-9. PubMed ID: 26367405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linguistic adaptation and validation of the Spanish version of the Benign Prostatic Hyperplasia-Patient Impact Measure (BPH-PIM).
    Llorente C; Ruiz M; Rejas Gutiérrez J; Esteban M; Villasante F; Hareendran A
    Clin Drug Investig; 2006; 26(2):103-12. PubMed ID: 17163240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical uroselectivity: a 3-year follow-up in general practice. BPH Group in General Practice.
    Lukacs B; Grange JC; McCarthy C; Comet D
    Eur Urol; 1998; 33 Suppl 2():28-33. PubMed ID: 9556193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ICS-'BPH' Study: the psychometric validity and reliability of the ICSmale questionnaire.
    Donovan JL; Abrams P; Peters TJ; Kay HE; Reynard J; Chapple C; De La Rosette JJ; Kondo A
    Br J Urol; 1996 Apr; 77(4):554-62. PubMed ID: 8777617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using the ICSOoL to measure the impact of lower urinary tract symptoms on quality of life: evidence from the ICS-'BPH' Study. International Continence Society--Benign Prostatic Hyperplasia.
    Donovan JL; Kay HE; Peters TJ; Abrams P; Coast J; Matos-Ferreira A; Rentzhog L; Bosch JL; Nordling J; Gajewski JB; Barbalias G; Schick E; Silva MM; Nissenkorn I; de la Rosette JJ
    Br J Urol; 1997 Nov; 80(5):712-21. PubMed ID: 9393291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, efficacy and impact on Patients' quality of life of a long-term treatment with the alpha(1)-blocker alfuzosin in symptomatic patients with BPH. The Italian Alfuzosin Co-Operative Group.
    Eur Urol; 2000 Jun; 37(6):680-6. PubMed ID: 10828668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
    Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
    BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the International Prostate Symptom Score (IPSS) in Chinese male patients with benign prostatic hyperplasia.
    Wong CK; Choi EP; Chan SW; Tsu JH; Fan CW; Chu PS; Cheung FK; Ma WK; Mah ISF; Yip SK; Hou SS; So HS; Lam CK
    Aging Male; 2017 Dec; 20(4):241-249. PubMed ID: 28787255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects.
    MacDonald R; Wilt TJ
    Urology; 2005 Oct; 66(4):780-8. PubMed ID: 16230138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.